Anderson 1983.

Methods	Randomised, parallel group, multicentre trial (North America). Method of randomisation: described as an "adaptive randomisation plan to ensure a satisfactory balance of factors hat were potentially important in the prognosis.." ITT: yes. Withdrawals: stated.
Participants	Baseline characteristics: 234 participants eligible, 47 (20%) classified as undifferentiated BL. Male:female: 184:50. Mean age not reported. 211 randomised (COMP ‐105, LSA2‐L2 protocol‐ 106) Tumour staging: Rappaport. Diagnosis: histopathological confirmation of childhood NHL. Entry criteria: < 18 years of age; no previous treatment for NHL; biopsy‐confirmed NHL. Exclusion criteria: not stated.
Interventions	COMP versus LSA2‐L2 treatment protocol (modified). SeeTable 1 for details of treatment protocol. Treatment duration: 18 months. Follow‐up: two to four years.
Outcomes	Overall survival (12 to 24 months). Failure‐free survival at 24 months. Relapse rate. Adverse events and toxicity.
Notes	Additional 23 participants followed during course of study but not randomly allocated to treatment group. Full text publication.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as an "adaptive randomisation plan to ensure a satisfactory balance of factors hat were potentially important in the prognosis.."
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	The authors reported on failure‐free survival, and adverse events/toxicity and accounted for those not included in the analysis.